Individuazione di nuovi BIOmarcatori PRognostici nell’OSteosarcoma: BIOPROS

Title

Code

BIOPROS

Type

Studio interventistico senza dispositivi e senza farmaci

Start Year

2025

Status

In Corso

Principal Investigator

051-6366102

toni.ibrahim@ior.it

Ibrahim Toni, BSc, MSc, MD, PhD

Director

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies

Operational unit that carry out the study

complex unit

Osteoncologia, Sarcomi dell'osso e dei tessuti molli, e Terapie Innovative

Director

Ibrahim Toni, BSc, MSc, MD, PhD

Go to the details >>

Documents and Videos attachament

Attachment

Informazioni sul trattamento dei dati personali e particolari - prot. BIOPROS

Wednesday 7 January 2026, 16:31

PG0016403_2025_06_BIOPROS_informativa_dati_ceavec_v.1.0_0_1__def.pdf

Attachment

Nulla osta alla conduzione dello studio prot. BIOPROS

Wednesday 7 January 2026, 16:29

PG0017500_2025_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Individuazione di nuovi BIOmarcatori PRognostici nell’OSteosarcoma: BIOPROS

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Individuazione di nuovi BIOmarcatori PRognostici nell’OSteosarcoma: BIOPROS

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in